KORU Medical Systems Initiates Phase III Clinical Trial for Rare Renal Disorder Treatment

KORU Medical Systems Partners for Clinical Trial in Renal Disorder Treatment

KORU Medical Systems, a leading medical technology company located in Mahwah, N.J., forms a strategic collaboration with a global pharmaceutical manufacturer to initiate a Phase III clinical trial. This trial aims to broaden the indications of an existing drug therapy designed for patients suffering from a rare renal disorder. Approximately 30,000 patients are affected by this condition, creating a demand for around 300,000 infusions annually. By evaluating the safety, efficacy, and overall performance of the drug in individuals facing complications from kidney transplants, KORU Medical seeks to contribute significantly to the management of this rare but impactful disorder.

The impetus behind this collaboration aligns with KORU Medical's commitment to improving drug delivery experiences. With their extensive expertise in the large volume subcutaneous market, the company has a proven track record of executing over 2 million infusions annually through its innovative Freedom Infusion System. This experience positions KORU Medical uniquely in the clinical trial landscape, where the company can leverage its technology to potentially enhance patient outcomes. Linda Tharby, President and CEO, highlights the trial's significance, suggesting that positive results could not only expand the company's reach to a new patient demographic but also dramatically enhance the quality of life for those affected by rare renal disorders.

KORU Medical's diversification into clinical trials supports their broader mission to develop, manufacture, and commercialize cutting-edge infusion solutions. Their product portfolio includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, as well as specialized tubing and safety needle sets. Since obtaining its FDA clearance in 1994, the Freedom System has played a pivotal role in facilitating self-administration for patients at home and enhancing delivery by healthcare professionals in clinical settings. This focus on innovative infusion technology underscores KORU Medical's potential to transform the treatment landscape for patients with complex medical needs.

In addition to advancing clinical trials, KORU Medical also assists biopharmaceutical companies in developing custom solutions across various drug categories. This capability not only reinforces the company’s role as a key player in the medical technology sector but also highlights its commitment to improving patient care through innovation and collaboration. As the Phase III trial progresses, KORU Medical remains optimistic about the potential impact of their research on the treatment of rare renal disorders.